Four Major Hospital Systems Race to Deploy AI as Federal Regulators Signal Crackdown
Cleveland Clinic, MetroHealth, and partners are rolling out virtual nursing and sepsis prediction tools even as the FDA considers physician-equivalent evaluation standards for generative AI medical devices.
A wave of artificial intelligence deployments is sweeping through Northeast Ohio's largest hospital systems, with Cleveland Clinic, MetroHealth System, University Hospitals, and Summa Health implementing AI tools across clinical operations—from virtual nursing platforms to sepsis prediction algorithms. The rapid adoption comes as healthcare AI spending reached $1.4 billion in 2025, nearly triple the previous year, and as federal regulators signal heightened scrutiny of AI-enabled medical devices.
Major Health Systems Commit to AI Infrastructure
MetroHealth System is deploying the Artisight Smart Hospital Platform for virtual nursing and language interpretation services at its Glick Center inpatient tower this fall, with expansion planned to Parma, Cleveland Heights, and Old Brooklyn facilities through 2027. Cleveland Clinic is using AI for sepsis identification, chronic disease management, virtual patient observation, automated medical note generation, and medical coding review, according to the source article.
University Hospitals has joined a 12-hospital national consortium designing AI-assisted tools for imaging and lab result analysis, with plans to expand its AI virtual nursing platform to nearly 3,000 beds. Summa Health in Akron partnered with eight technology companies to deploy AI for chest scan analysis, specialist referrals, and automated supply ordering. Southwest General Medical Center uses AI for appointment reminders, admittance paperwork, and electronic health record documentation.
The deployment scale reflects broader industry trends: nearly 70% of clinicians now use AI tools daily, according to a 2026 industry report cited in the source, and approximately 22% of U.S. healthcare organizations used AI tools in 2025.
Clinical Leaders Emphasize Transformation Over Incremental Change
Dr. Tomislav Mihaljevic, Cleveland Clinic CEO, stated the organization is "reimagining the ecosystem of healthcare delivery" with an AI-first approach rather than layering AI onto existing processes. Dr. Jorge Guzman, Cleveland Clinic's executive vice president for U.S. markets, identified disease management—particularly high-fatality conditions like sepsis—as the biggest day-to-day AI impact area.
However, clinical leaders are voicing caution about implementation risks. Dr. Steve Davis, CEO of Cincinnati Children's Hospital, warned that AI adoption alone will not improve performance "without equal investment in the human judgment, analytical skill, and training required to use it safely and effectively," according to the source article. The concern centers on AI platforms' tendency to "hallucinate," producing misleading responses or inconsistent answers to identical questions.
FDA Signals Regulatory Tightening
The rapid adoption is prompting federal regulatory scrutiny. Acting FDA Commissioner Kyle Diamantes announced the agency is considering evaluating generative AI-enabled medical devices using processes similar to physician evaluation, according to the source. The potential regulatory shift comes as health systems accelerate deployments across patient-facing and clinical decision-support applications.
The regulatory uncertainty creates a complex environment for hospital systems balancing operational efficiency gains—particularly in addressing staffing shortages and administrative burden—against compliance requirements and patient safety obligations. The multi-hospital consortium model adopted by University Hospitals suggests health systems are pursuing collaborative development partnerships rather than relying solely on vendor relationships, potentially reshaping the competitive landscape for healthcare AI companies.
Sources
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.